



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Francesca Chiodi
Serial No. : 09/719,646
Filing Date : February 28, 2001
Examiner : Alana M. Harris
Group Art Unit : 1642
Entitled : FAS PEPTIDES AND ANTIBODIES
FOR MODULATING APOPTOSIS

1642

RECEIVED

NOV 06 2003

TECH CENTER 1600/2900

Suite 2400
1601 Market Street
Philadelphia, PA 19103
(215) 563-4100 (telephone)
(215) 563-4044 (facsimile)
Our File No. 0380-P02373US0

Certificate of Mailing Under 37 C.F.R. §1.8(a):

I hereby certify that this correspondence is being deposited on October 29, 2003 with the United States Postal Service as first-class mail in an envelope properly addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janice M. Nightlinger

Janice M. Nightlinger

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO OFFICIAL COMMUNICATION DATED SEPTEMBER 23, 2003

Dear Sir:

The undersigned attorney received an Official Communication dated September 23, 2003 concerning the above-identified patent application. The Official Communication indicates that the Traversal and Request for Reconsideration of Requirement for Restriction, filed in response to the November 19, 2001

Restriction Requirement in this application is deemed not fully responsive. In this connection, the Official Communication stated "Applicant is advised to review the election and clearly set for the Group for examination".

As a preliminary matter, it is noted that the above-mentioned September 23, 2003 Official Communication does not set a shortened statutory period for response. It is assumed therefore, a maximum period of six (6) months is allowed for filing a response, as provided in 37 C.F.R. §1.134.

Applicant once again elects, with traverse (for the reasons set forth in Applicant's response filed July 1, 2003, which are incorporated by reference herein), the invention designated as Group XVI in the April 1, 2003 Restriction Requirement, which is the subject matter of Claims 49-52 employing a human Fas peptide fragment having SEQ ID No. 4.

In the event that a fee is required, the Commissioner is authorized to charge Deposit Account No. 04-1406 of the undersigned attorneys. A duplicate copy of this paper is enclosed.

Early and favorable action on the merits of this application is respectfully requested.

DANN DORFMAN HERRELL and
SKILLMAN, P.C.

Attorneys for Applicant

By Patrick J. Hagan
Patrick J. Hagan
Registration No. 27,643

PJH:jmn